Vertex ends Hep C drug sales, ousted by Sovaldi’s prominent market hold

Boston-based Vertex Pharmaceuticals will no longer sell or distribute its Incivek hepatitis C treatment, largely due to newly available drugs such as Gilead’s Sovaldi, according to a Reuters report.

Advertisement

Incivek will not be available for patients after Oct. 14. While the drug will no longer be in the hepatitis C treatment market, the company has not indicated when it would stop making the drug, according to the report.

More articles on Sovaldi:

Despite price, Sovaldi still treatment of choice for Hep C
Sovaldi generates $3.48B in Q2 sales
60% of Americans Are Worried They Won’t Be Able to Afford Specialty Drugs

 

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

From fragmentation to operational flow: Solving the healthcare workforce puzzle

Tuesday, August 11
1:00 PM - 2:00 PM CDT

Presenters: Dr. Pat Hunt, QGendaAndrea Daugherty, MHA, CISSP, CHCIO, CDH-E, Arrowhead Regional Medical CenterElizabeth Lindsay-Wood, MBA, CHCIO, CDH-E, Moffitt Cancer CenterDeb Muro, El Camino HealthJohn Tejeda, D.H.A., MLS, MPAS, DFAAPA, LSSBB, FACHE, Vascular and Neuroscience Institute

Advertisement

Next Up in Supply Chain

Advertisement

Comments are closed.